Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of CSL112 in acute myocardial infarction
jRCT2080224998Phase 3Completed
- Sponsor
- CSL Limited
- Start
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in myocardial infarction (MI), acute coronary syndrome (ACS) and cardiac morbidity comparing CSL112 6 g with Placebo (albumin solution) (2 arms). Primary endpoint: Composite of cardiovascular death, myocardial infarction, or stroke through Day 90. Started Dec 2019; status: completed.
02
Drugs
CSL112
03
Conditions
myocardial infarction (MI)acute coronary syndrome (ACS)cardiac morbidity
Beyond the preview
Go deeper on jRCT2080224998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224998.